SARS-CoV-2 Seropositivity in Nursing Home Staff and Residents during the First SARS-CoV-2 Wave in Flanders, Belgium.

SARS-CoV-2 Seropositivity in Nursing Home Staff and Residents during the First SARS-CoV-2 Wave in Flanders, Belgium.

Publication date: Sep 14, 2024

(1) Background: early in the COVID-19 pandemic, reverse transcription polymerase chain reaction (RT-PCR) testing was limited. Assessing seroprevalence helps understand prevalence and reinfection risk. However, such data are lacking for the first epidemic wave in Belgian nursing homes. Therefore, we assessed SARS-CoV-2 seroprevalence and cumulative RT-PCR positivity in Belgian nursing homes and evaluated reinfection risk. (2) Methods: we performed a cross-sectional study in nine nursing homes in April and May 2020. Odds ratios (ORs) were calculated to compare the odds of (re)infection between seropositive and seronegative participants. (3) Results: seroprevalence was 21% (95% CI: 18-23): 22% (95% CI: 18-25) in residents and 20% (95% CI: 17-24) in staff. By 20 May 2020, cumulative RT-PCR positivity was 16% (95% CI: 13-21) in residents and 8% (95% CI: 6-12) in staff. ORs for (re)infection in seropositive (compared to seronegative) residents and staff were 0. 22 (95% CI: 0. 06-0. 72) and 3. 15 (95% CI: 1. 56-6. 63), respectively. (4) Conclusion: during the first wave, RT-PCR test programmes underestimated the number of COVID-19 cases. The reinfection rate in residents was 3%, indicating protection, while it was 21% in staff, potentially due to less cautious health behaviour. Future outbreaks should use both RT-PCR and serological testing for complementary insights into transmission dynamics.

Open Access PDF

Concepts Keywords
Belgium Adult
Nursing Aged
Pandemic Aged, 80 and over
Polymerase Antibodies, Viral
Antibodies, Viral
Belgium
COVID-19
COVID-19
COVID-19 Serological Testing
Cross-Sectional Studies
Female
Health Personnel
Humans
Male
Middle Aged
Nursing Homes
nursing homes
Prevalence
Reinfection
reinfection
RT-PCR testing
SARS-CoV-2
SARS-CoV-2
Seroepidemiologic Studies
seroprevalence

Semantics

Type Source Name
drug DRUGBANK Etoperidone
disease MESH COVID-19 pandemic
disease MESH reinfection
disease MESH infection
drug DRUGBANK Coenzyme M
disease MESH Infectious Diseases
drug DRUGBANK Gold
disease IDO symptom
disease MESH influenza
disease MESH dementia
disease IDO blood
drug DRUGBANK Oxygen
disease MESH morbidities

Original Article

(Visited 1 times, 1 visits today)